|Bid||15.50 x 800|
|Ask||23.50 x 800|
|Day's Range||15.65 - 17.32|
|52 Week Range||7.42 - 37.25|
|PE Ratio (TTM)||13.76|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.00|
XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs. XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future. For more information, visit www.xoma.com.
Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Emeryville, California-based company said it had a loss of 23 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
EMERYVILLE, Calif., Aug. 07, 2018-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced its second quarter 2018 financial results.. “We continue ...
NEW YORK, Aug. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alleghany ...
XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 22, 2018. “We believe XOMA’s addition to these Russell indexes will enhance our visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer at XOMA. The Russell 3000® Index is a market capitalization-weighted equity index that tracks the performance of the largest 3,000 U.S. stocks.
The Berkeley, California-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
The Berkeley, California-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $5.4 million in the period. For the year, the company reported net income of $14.6 ...
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.